City of Hope Medical Center — Biomedical Watch V2

Traitements14programmes

Essais9liés

Publications30liées

SourceDBlocale

Traitements

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
AcalabrutinibThe purpose of this study is to investigate the efficacy and safety of fixed-duration sonrotoclax (also known as BGB-11417) plus zanubrutinib (also known as BGB-3111) (SZ) compared with fixed-duration of venetoclax plus acalabrutinib (AV) in participants with previously untreated chronic lymphocytic leukemia (CLL).	Cancer, SEP	Phase 2	À vérifier	United States	À vérifier
ASCTThis phase II clinical trial studies how well yttrium Y 90 ibritumomab tiuxetan, rituximab, and high-dose chemotherapy followed by peripheral blood stem cell transplant in treating patients with relapsed B-cell non-Hodgkin lymphoma. Monoclonal antibodies, such as yttrium Y 90 ibritumomab tiuxetan and rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Radiolabeled monoclonal antibodies can find tumor cells and carry tumor-killing substances to them without harming normal cells. Giving monoclonal antibody therapy, radioimmunotherapy (RIT), and high-dose combination chemotherapy before a peripheral blood stem cell transplant may be an effective treatment for non-Hodgkin lymphoma.	SEP	Phase 2	Thérapie cellulaire	United States	À vérifier
CarmustineThis phase II trial studies the side effects and how well carmustine, etoposide, cytarabine and melphalan together with antithymocyte globulin before a stem cell transplant works in treating patients with autoimmune neurologic disease that did not respond to previous therapy. In autoimmune neurological diseases, the patient's own immune system 'attacks' the nervous system which might include the brain/spinal cord and/or the peripheral nerves. Giving high-dose chemotherapy, including carmustine, etoposide, cytarabine, melphalan, and antithymocyte globulin, before a stem cell transplant weakens the immune system and may help stop the immune system from 'attacking' a patient's nervous system. When the patient's own (autologous) stem cells are infused into the patient they help the bone marrow make red blood cells, white blood cells, and platelets so the blood counts can improve.	Myasthénie, SEP	Phase 2	Thérapie cellulaire	United States	À vérifier
F-18 16 Alpha-FluoroestradiolThis phase II trial tests how well stereotactic body radiation therapy (SBRT) works in treating patients with estrogen receptor positive (ER +) breast cancer that has spread from where it first started to other places in the body (metastatic) and has limited disease progression (oligoprogression). Currently, the standard of care for breast cancer patients with oligoprogressive disease is to change systemic therapy when progression occurs. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. SBRT is a type of external radiation therapy that uses special equipment to position a patient and precisely deliver radiation to tumors in the body (except the brain). The total dose of radiation is divided into smaller doses (fractions) given over several days. This type of radiation therapy helps spare normal tissue and has been shown to improve survival. SBRT may kill more tumor cells and allow patients with oligoprogressive ER + metastatic breast cancer to continue taking current systemic treatment. This trial also tests how well ER targeted positron emission tomography (PET)/ computed tomography (CT) imaging, using FES, works in identifying progressive disease in patients with ER + metastatic breast cancer. FES, a radiolabeled substance, binds to estrogen receptors and gives off radiation that can be detected by a PET scan. The PET scan, an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, FES, forms an image that shows where tumor cells with estrogen receptors can be found in the body. CT images use x-rays to provide an exact outline of organs. FES PET/CT may improve identification of progressive disease in patients with ER + metastatic breast cancer.	Cancer	Phase 2	Ralentissement de la progression	United States	À vérifier
IfosfamideThis phase II trial studies the effect of polatuzumab vedotin, rituximab, ifosfamide, carboplatin, and etoposide as initial salvage therapy in treating patients with diffuse large B-cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Polatuzumab vedotin is a monoclonal antibody, polatuzumab, linked to a toxic agent called vedotin. Polatuzumab attaches to CD79b positive cancer cells in a targeted way and delivers vedotin to kill them. Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Chemotherapy drugs, such as ifosfamide, carboplatin, and etoposide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy with immunotherapy may kill more cancer cells in patients with diffuse large B-cell lymphoma.	Cancer	Phase 2	À vérifier	United States	À vérifier
Lumbar PunctureBackground: Mature T-cell malignancies (TCMs) are a rare group of cancers that usually do not have effective treatments or cures. Because of this, participants with TCMs often relapse and have a poor overall prognosis. This trial is testing if combining several drugs against TCMs can be a more effective. Primary Objective: To test if the combination of romidepsin, CC-486 (5-azacitidine), dexamethasone, and lenalidomide (RAdR) can be given safely to participants with relapsed or treatment refractory TCM. Other (Secondary) Objective: Measure the activity of this combination treatment. Eligibility: People age 18 and older who have a failed or relapsed after standard treatments for mature TCMs. Design: Participants will be screened for eligibility by performing the following tests or procedures: Physical exam Medical history Medicine review Blood and urine tests Symptom review Bone marrow examination Total Body imaging scans or x-rays Tumor biopsy Participants will have blood tests during treatment to make sure their blood cell counts are okay. Romidepsin is infused through an intravenous (IV) placed in one of the veins usually in the arm. Lenalidomide, dexamethasone, and CC-486 (5-azacitidine) are pills or capsules taken by mouth. Participants are asked to keep a diary of when they take their pills to make sure they are taking these medicines properly. Participants will have tumor imaging scans after every 2nd cycle (or 6 weeks) to check if the treatment is working. If the doctors are concerned the cancer has spread to the brain and/or spine, they will have scans of the area(s) and a sampling of the fluid around the brain/spine which is obtained through a small needle inserted into the lower part of the back for a short time to collect the fluid. This procedure is called a spinal tap or lumbar puncture. Participants who have tumor in their skin will have repeat exams of their skin and sometimes photographs taken of these areas to see if the treatment is working. Participants will also be asked to give blood, saliva, and sometimes have optional biopsies of their tumor where these tests are done for research purposes. After they have completed the protocol treatment (6 cycles), they will be asked to return to clinic 30 days after treatment has ended, then every other month (or 60 days) for the first 6 months, then every 3 months (90 days) for 2 years, and then every 6 months for years 2 to 4 after completing treatment. After 4.5 years, they will be seen once a year.	Cancer, Sclérose latérale amyotrophique, SEP	Phase 1	Traitement symptomatique	United States	À vérifier
MelphalanThis phase II trial studies the side effects and how well carmustine, etoposide, cytarabine and melphalan together with antithymocyte globulin before a stem cell transplant works in treating patients with autoimmune neurologic disease that did not respond to previous therapy. In autoimmune neurological diseases, the patient's own immune system 'attacks' the nervous system which might include the brain/spinal cord and/or the peripheral nerves. Giving high-dose chemotherapy, including carmustine, etoposide, cytarabine, melphalan, and antithymocyte globulin, before a stem cell transplant weakens the immune system and may help stop the immune system from 'attacking' a patient's nervous system. When the patient's own (autologous) stem cells are infused into the patient they help the bone marrow make red blood cells, white blood cells, and platelets so the blood counts can improve.	Myasthénie, SEP	Phase 2	Thérapie cellulaire	United States	À vérifier
Polatuzumab VedotinThis phase II trial studies the effect of polatuzumab vedotin, rituximab, ifosfamide, carboplatin, and etoposide as initial salvage therapy in treating patients with diffuse large B-cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Polatuzumab vedotin is a monoclonal antibody, polatuzumab, linked to a toxic agent called vedotin. Polatuzumab attaches to CD79b positive cancer cells in a targeted way and delivers vedotin to kill them. Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Chemotherapy drugs, such as ifosfamide, carboplatin, and etoposide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy with immunotherapy may kill more cancer cells in patients with diffuse large B-cell lymphoma.	Cancer	Phase 2	À vérifier	United States	À vérifier
Positron Emission TomographyThis pilot early phase I trial studies how well fluorothymidine F-18 positron emission tomography (PET) works in imaging patients with intermediate or high grade soft tissue sarcoma. Fluorothymidine F-18 PET may provide useful information about the tumor's response to treatment and may give the doctors early results that would better help to plan the post-surgical therapy.	Cancer, SEP	Phase 2	À vérifier	United States	À vérifier
Stereotactic Body Radiation TherapyThis phase I trial tests the safety, side effects, and best dose of camonsertib in combination with stereotactic body radiation therapy in controlling disease in patients with head and neck squamous cell cancer that has come back after a period of improvement (recurrent) or that cannot be removed by surgery (unresectable). Camonsertib may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell growth. Stereotactic body radiation therapy is a type of external radiation therapy that uses special equipment to position a patient and precisely deliver radiation to tumors in the body (except the brain). The total dose of radiation is divided into smaller doses given over several days. This type of radiation therapy helps spare normal tissue. Giving camonsertib in combination with stereotactic body radiation therapy may help control disease in patients with recurrent or unresectable head and neck squamous cell cancers.	Cancer	Phase 2	À vérifier	United States	À vérifier
Lumbar PunctureBackground: Mature T-cell malignancies (TCMs) are a rare group of cancers that usually do not have effective treatments or cures. Because of this, participants with TCMs often relapse and have a poor overall prognosis. This trial is testing if combining several drugs against TCMs can be a more effective. Primary Objective: To test if the combination of romidepsin, CC-486 (5-azacitidine), dexamethasone, and lenalidomide (RAdR) can be given safely to participants with relapsed or treatment refractory TCM. Other (Secondary) Objective: Measure the activity of this combination treatment. Eligibility: People age 18 and older who have a failed or relapsed after standard treatments for mature TCMs. Design: Participants will be screened for eligibility by performing the following tests or procedures: Physical exam Medical history Medicine review Blood and urine tests Symptom review Bone marrow examination Total Body imaging scans or x-rays Tumor biopsy Participants will have blood tests during treatment to make sure their blood cell counts are okay. Romidepsin is infused through an intravenous (IV) placed in one of the veins usually in the arm. Lenalidomide, dexamethasone, and CC-486 (5-azacitidine) are pills or capsules taken by mouth. Participants are asked to keep a diary of when they take their pills to make sure they are taking these medicines properly. Participants will have tumor imaging scans after every 2nd cycle (or 6 weeks) to check if the treatment is working. If the doctors are concerned the cancer has spread to the brain and/or spine, they will have scans of the area(s) and a sampling of the fluid around the brain/spine which is obtained through a small needle inserted into the lower part of the back for a short time to collect the fluid. This procedure is called a spinal tap or lumbar puncture. Participants who have tumor in their skin will have repeat exams of their skin and sometimes photographs taken of these areas to see if the treatment is working. Participants will also be asked to give blood, saliva, and sometimes have optional biopsies of their tumor where these tests are done for research purposes. After they have completed the protocol treatment (6 cycles), they will be asked to return to clinic 30 days after treatment has ended, then every other month (or 60 days) for the first 6 months, then every 3 months (90 days) for 2 years, and then every 6 months for years 2 to 4 after completing treatment. After 4.5 years, they will be seen once a year.	Sclérose latérale amyotrophique	Non applicable	Traitement symptomatique	France	À vérifier
AcalabrutinibThe purpose of this study is to investigate the efficacy and safety of fixed-duration sonrotoclax (also known as BGB-11417) plus zanubrutinib (also known as BGB-3111) (SZ) compared with fixed-duration of venetoclax plus acalabrutinib (AV) in participants with previously untreated chronic lymphocytic leukemia (CLL).	Cancer	Phase 2	À vérifier	United States	À vérifier
AcalabrutinibThe purpose of this study is to investigate the efficacy and safety of fixed-duration sonrotoclax (also known as BGB-11417) plus zanubrutinib (also known as BGB-3111) (SZ) compared with fixed-duration of venetoclax plus acalabrutinib (AV) in participants with previously untreated chronic lymphocytic leukemia (CLL).	SEP	Phase 2	À vérifier	United States	À vérifier
AcalabrutinibThe purpose of this study is to investigate the efficacy and safety of fixed-duration sonrotoclax (also known as BGB-11417) plus zanubrutinib (also known as BGB-3111) (SZ) compared with fixed-duration of venetoclax plus acalabrutinib (AV) in participants with previously untreated chronic lymphocytic leukemia (CLL).	SEP	Phase 2	À vérifier	United States	À vérifier

Essais cliniques

Molécule	Indication / population	Phase	NCT	Titre	Statut
Biospecimen Collection	Cancer	Phase 2	NCT06260033	Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer	RECRUITING
Rituximab	SEP	Phase 2	NCT00695409	Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma	COMPLETED
Biospecimen Collection	SEP	Phase 1	NCT06922604	Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System Lymphoma	SUSPENDED
Acalabrutinib	SEP	Phase 2	NCT04169737	Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	RECRUITING
Acalabrutinib	SEP	Phase 2	NCT07582159	Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	RECRUITING
Acalabrutinib	Cancer	Phase 2	NCT04115631	A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma	ACTIVE_NOT_RECRUITING
carboplatin	Cancer	Phase 2	NCT04665765	Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma	ACTIVE_NOT_RECRUITING
Lumbar Puncture	Sclérose latérale amyotrophique	Non applicable	NCT07213440	PremodiALS — Identification of Early Markers for ALS	RECRUITING
Biospecimen Collection	Cancer	Phase 2	NCT05722288	Time-Restricted Eating Versus Nutritional Counseling for the Reduction of Radiation or Chemoradiation Tx Side Effects in Patients With Prostate, Cervical, or Rectal Cancers	ACTIVE_NOT_RECRUITING

Publications

Molécule	Titre	Journal
ASCT	Correlation Between SGK1 Expression Level and Multiple Myeloma Progression After Autologous Hematopoietic Stem Cell Transplantation.	Biochemical genetics
ASCT	Venetoclax Plus Hypomethylating Agent for 7- Versus 14- Versus 21- Versus 28-Day Cycles in Newly-Diagnosed Acute Myeloid Leukemia: ELN and Mayo Genetic Risk-Stratified Analysis in 540 Patients.	American journal of hematology
ASCT	Serologic follow-up in patients with multiple myeloma without repeated bone marrow studies: a single-institution experience.	Hematology (Amsterdam, Netherlands)
Polatuzumab Vedotin	Diffuse large B-cell lymphoma involving the vagina and a pre-existing uterine leiomyoma.	Radiology case reports
Polatuzumab Vedotin	Low lymphoma macrophage infiltration predicts poor outcomes for R-CHOP- but not Pola-R-CHP-treated patients with DLBCL.	Blood neoplasia
Carmustine	Atomic-scale insights into the interaction mechanism of carmustine on chitosan nanocarriers: A combined DFT and molecular dynamics study.	International journal of biological macromolecules
Carmustine	Multi-Omics Integration Identifies a Five-Gene Metabolic Signature With Experimental Validation in Clear Cell Renal Cell Carcinoma.	Cancer reports (Hoboken, N.J.)
Melphalan	Melphalan's Effect on Testicular Prepubertal Rats: Induction of Autophagy and Apoptosis, Modulated by the Potential of Chrysin.	Journal of medicinal food
Melphalan	Fludarabine, Busulfan, Thiotepa, and Melphalan: A Novel Low-Toxicity Myeloablative Conditioning Regimen for Haploidentical HSCT in Children and Adolescents Aged ≥7 Years With Transfusion-Dependent β-Thalassemia.	Pediatric blood & cancer
Melphalan	Self-assembled melphalan hydrogel with nitric oxide delivery for synergistic chemoimmunotherapy.	Journal of colloid and interface science
Carmustine	The Role of Cellular Glutathione Redox Cycle and Glutathione in the Regulation of Ileum Contractility.	International journal of molecular sciences
Carmustine	High-dose chemotherapy followed by autologous stem-cell transplantation versus non-myeloablative consolidation in primary CNS lymphoma (MATRix/IELSG43): a randomised phase 3 trial.	Lancet (London, England)
Carmustine	Triple-targeted artificial extracellular vesicles for enhanced glioma therapy via synergistic chemomagnetic penetration of the blood-brain barrier.	Colloids and surfaces. B, Biointerfaces
Melphalan	A computational study of perylene diimide as a potential nanocarrier for multiple drugs: adsorption, stability and release mechanisms.	Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy
Melphalan	Anti-myeloma mechanisms of the selective NF-κB inhibitor QNZ.	Molecular therapy. Oncology
Lumbar Puncture	Implementation of a specialized inpatient HIV care model and in-hospital mortality in South Brazil: a before-after study.	Lancet regional health. Americas
Lumbar Puncture	CNS infection presenting as a periaqueductal "soap-bubble" lesion causing obstructive hydrocephalus with refractory CSF diversion.	Radiology case reports
Lumbar Puncture	Oral body temperature and cerebrospinal fluid pTau181 in older adults at increased risk of Alzheimer's disease.	Neurobiology of aging
Positron Emission Tomography	Desmoid Fibromatosis of the Gastric Wall Mimicking Needle Tract Seeding after Endoscopic Ultrasound-Guided Fine-Needle Biopsy for Pancreatic Cancer: A Case Report.	DEN open
Positron Emission Tomography	Ulcerative Esophagitis With Marked Eosinophilic Infiltration and Fluorodeoxyglucose-Positron Emission Tomography Positivity Requiring Differentiation From Esophagogastric Junction Carcinoma.	DEN open
Positron Emission Tomography	Reassessing Bone Marrow Aspirate and Trephine Biopsies in Staging for Paediatric and Young Adult Patients With Ewing Sarcoma and Rhabdomyosarcoma.	Pediatric blood & cancer
Positron Emission Tomography	A multicenter prediction model for false-positive clinical nodal disease in < 4-cm NSCLC: clinical implications for upfront surgery versus neoadjuvant therapy.	BMC cancer
Positron Emission Tomography	Multifocal xanthogranulomatous inflammation of the urinary tract mimicking metastatic urothelial carcinoma: A case report.	Medicine
Positron Emission Tomography	Vitrectomy Status Alters Early Intravitreal Drug Distribution: An Ex Vivo PET-CT Study.	Investigative ophthalmology & visual science
Positron Emission Tomography	A comprehensive review of C-, F-, and I-labeled radiotracers targeting cyclooxygenase-2 over the past two decades.	Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents
Positron Emission Tomography	Radiolabeled Mesoporous Silica Nanosystem Enables Long-Term Cell Tracking In Vivo.	Molecular pharmaceutics
Positron Emission Tomography	Ga-citrate visualization study on ferroptosis through transferrin receptor 1 in periodontitis.	BMC oral health
Positron Emission Tomography	Isolated Cardiac Sarcoidosis With Marfan Syndrome Following Cardiovascular Surgery: A Case Report.	Cureus
Positron Emission Tomography	Radioluminescence microscopy of tumor organoids enabled by a reconfigurable high-resolution imaging setup.	EJNMMI research
Positron Emission Tomography	Evaluation of [18F]MFPBG: a novel automatically radiolabeled probe for NET PET imaging.	EJNMMI research